Fulcrum Therapeutics, Inc. (NASDAQ: FULC)

Sector: Healthcare Industry: Biotechnology CIK: 0001680581
Market Cap 630.67 Mn
P/B 3.18
P/E -8.87
P/S 0.00
ROIC (Qtr) -38.15
Div Yield % 0.00
Rev 1y % (Qtr) 0.00
Total Debt (Qtr) 7.01 Mn
Debt/Equity (Qtr) 0.04

About

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, operates in the industry of developing treatments for rare diseases. The company is specifically focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum Therapeutics has developed a proprietary product engine, FulcrumSeek, which is used to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined diseases. The...

Read more

Price action

Investment thesis

Bull case

  • Healthy cash reserves of 48.28M provide 20.56x coverage of short-term debt 2.35M, demonstrating strong liquidity position and minimal refinancing risk.
  • Strong tangible asset base of 214.86M provides 30.65x coverage of total debt 7.01M, indicating robust asset backing and low credit risk.
  • Short-term investments of 153.57M provide solid 23.89x coverage of other current liabilities 6.43M, indicating strong liquidity.
  • Tangible assets of 214.86M provide robust 33.43x coverage of other current liabilities 6.43M, indicating strong asset backing.
  • Cash reserves of 48.28M provide solid 245.07x coverage of other non-current liabilities 197000, indicating strong liquidity.

Bear case

  • Operating cash flow of (60.03M) barely covers its investment activities of 34.03M, with a coverage ratio of -1.76, indicating heavy reliance on external financing for growth which may not be sustainable in a tighter credit environment.
  • Investment activities of 34.03M provide weak support for R&D spending of 52.40M, which is 0.65x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • Short-term investments of 153.57M significantly exceed cash reserves of 48.28M, which is 3.18x, indicating potentially excessive yield-seeking behavior at the expense of liquidity.
  • The company's operating cash flow of (60.03M) shows concerning coverage of stock compensation expenses of 11.88M, with a -5.05 ratio indicating potential earnings quality issues.
  • Free cash flow of (60.41M) provides weak coverage of capital expenditures of 386000, with a -156.51 ratio suggesting additional external financing needs for growth initiatives.

Peer comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,446.17 Bn -1,569.17 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 439.23 Bn 6,407.40 88.33 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 120.62 Bn 32.82 10.29 1.83 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 84.40 Bn 18.44 5.92 2.71 Bn
5 ALNY Alnylam Pharmaceuticals, Inc. 56.13 Bn 1,288.39 17.49 3.21 Bn
6 ARGX Argenx Se 47.89 Bn 31.79 24,973.95 -
7 BNTC Benitec Biopharma Inc. 42.45 Bn -1,015.00 0.00 0.00 Bn
8 INSM INSMED Inc 32.67 Bn -27.60 73.08 0.74 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 2.77 12.96
EV to Cash from Ops. EV/CFO -9.90 23.73
EV to Debt EV to Debt 84.79 772.65
EV to EBIT EV/EBIT -8.36 -11.30
EV to EBITDA EV/EBITDA -7.42 7.11
EV to Free Cash Flow [EV/FCF] EV/FCF -9.84 22.12
EV to Market Cap EV to Market Cap 0.94 68.89
EV to Revenue EV/Rev 0.00 199.70
Price to Book Value [P/B] P/B 3.18 22.62
Price to Earnings [P/E] P/E -8.87 -12.30
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Div Coverage (Qtr) 0.00 -12.02
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 0.17
Dividend per Basic Share Div per Share (Qtr) 0.00 0.01
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 -0.15
Interest Coverage Int. cover (Qtr) 0.00 857.11
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex 1y % (Qtr) -211.29 -27.24
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) -34.61 747.06
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % EBIAT 1y % (Qtr) -297.00 -48.21
EBITDA Growth (1y) % EBITDA 1y % (Qtr) -178.80 -2.09
EBIT Growth (1y) % EBIT 1y % (Qtr) -297.00 -57.79
EBT Growth (1y) % EBT 1y % (Qtr) -297.00 -14.35
EPS Growth (1y) % EPS 1y % (Qtr) -293.10 -30.88
FCF Growth (1y) % FCF 1y % (Qtr) -591.31 -32.51
Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) 0.00 227.96
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.00 0.14
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.00
Cash Ratio Cash Ratio (Qtr) 4.15 3.79
Current Ratio Curr Ratio (Qtr) 17.70 7.23
Debt to Equity Ratio Debt/Equity (Qtr) 0.04 0.42
Interest Cover Ratio Int Coverage (Qtr) 0.00 857.11
Times Interest Earned Times Interest Earned (Qtr) 0.00 857.11
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) 0.00 -18,509.94
EBIT Margin % EBIT Margin % (Qtr) 0.00 -18,862.18
EBT Margin % EBT Margin % (Qtr) 0.00 -19,783.19
Gross Margin % Gross Margin % (Qtr) 0.00 -8.62
Net Profit Margin % Net Margin % (Qtr) 0.00 -19,732.60